Artivion Announces Convertible Notes Exchange Agreement

Artivion ( (AORT) ) has provided an update.

On May 14, 2025, Artivion, Inc. announced that it entered into privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due July 1, 2025. The agreements involve exchanging approximately $94.54 million in principal amount of these notes for shares of the company’s common stock, with the number of shares determined by the stock’s average trading price over a specified period. The transaction is expected to close around May 28, 2025, and will leave approximately $5.46 million of the notes outstanding. This strategic move is anticipated to impact Artivion’s financial structure and market positioning, potentially affecting stakeholders by altering the company’s debt and equity composition.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Spark’s Take on AORT Stock

According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.

Artivion’s stock reflects a mix of solid revenue growth and profitability challenges. The earnings call provided a positive outlook with raised guidance and strong product performance, offsetting cybersecurity and regional revenue issues. Technical indicators show strong momentum, but valuation concerns remain due to negative earnings.

To see Spark’s full report on AORT stock, click here.

More about Artivion

Artivion, Inc., headquartered in suburban Atlanta, Georgia, is a medical device company that specializes in providing solutions for cardiac and vascular surgeons dealing with aortic diseases. The company’s primary products include aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells its products in over 100 countries worldwide.

Average Trading Volume: 537,148

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.23B

For detailed information about AORT stock, go to TipRanks’ Stock Analysis page.